News

Sandra Sulser récompensée : Son projet InnoTREK « BioMe » remporte le prix Isabelle Musy 2016

May 3, 2016

photo Sandra Sulser 652x367

Avec son projet de Start-up BioMe, Sandra Sulser a remporté le Prix Isabelle Musy 2016. Doté de CHF 50’000.-, ce prix a pour objectif de soutenir une femme entrepreneuse dans la création de sa start-up en Suisse latine.

Le projet BioMe tend à développer un nouveau traitement pour les maladies inflammatoires de l’intestin en procédant à l’administration chez le patient d’un extrait de microbiome intestinal d’un donneur sain compatible avec la flore intestinale du patient. L’objectif est la proposer une administration facilité sous forme de gélules ou de suppositoires.

Sandra Sulser a commencé son projet à la fin de son PhD dans le département de Microbiologie Fondamentale du Professeur Jan Van Der Meer. Actuellement elle travaille aussi en étroite collaboration avec Dr Michel Maillard du service de gastro-entérologie du CHUV.

A l’automne 2014, Sandra Sulser avait présenté son projet au PACTT dans le cadre de la bourse InnoTREK. Son projet avait été retenu et elle avait ainsi obtenu le financement d’une bourse de CHF 100’000.- par la FIT pour une année.

Ainsi Sandra Sulser est après Véronica Ponce de Leon  déjà la deuxième lauréate d’une bourse InnoTREK à être distinguée par le prix Isabelle Musy.

Le PACTT souhaite plein succès à Sandra Sulser dans son parcours d’entrepreneuse !

Lab-Innovation Award 2016 : Félicitations aux porteurs du projet EzeCHiel développé par l’HEIG-VD et le CHUV

April 29, 2016

IMG_0636

De gauche à droite: Robert Hooper : HEIG-VD, Séverine Petitprez : CHUV, Yann Sutter: HEIG-VD, Yann Thoma: HEIG-VD, Thierry Buclin: CHUV

Du 13 au 14 avril, le Palais de Beaulieu à Lausanne hébergeait le salon Lab Innovations 2016 exposant les dernières nouveautés en matière de technologies de laboratoire. Le projet EzeCHieL, récompensé du Lab-Innovation Award 2016, catégorie recherche, est le fruit d’une collaboration entre l’équipe de Pharmacologie clinique du CHUV (Prof. T. Buclin) ­et celle de l’institut REDS (Reconfigurable & Embedded Digital Systems, Prof. Y. Thoma) rattaché au groupe Health Engineering and Economics de la haute école HEIG-VD à Yverdon, qui a notamment comme mission  de favoriser les synergies entre l’ingénierie et la santé.
Le logiciel développé dans le cadre de ce projet fournit une assistance conviviale au suivi thérapeutique des médicaments (Therapeutic Drug Monitoring – TDM). Il propose une interprétation des mesures de concentrations sanguines de médicaments et prédit quelle sera leur évolution après ajustement des posologies par le prescripteur.
Ce prix, décerné pour la première année dans le cadre du salon Lab Innovations 2016, récompense une application prometteuse découlant d’un projet de recherche innovant. Il met en lumière la fructueuse collaboration entre le CHUV et la HEIG-VD.
A relever que ce projet est soutenu par une bourse InnoPACTT/FIT, décernée au Dr Séverine Petitprez et destinée à la création d’une spin off basée sur cette innovation.

Source: site CHUV

InnoPACTT: a financial support to create your start-up

March 2, 2016

Spring CALL 2016

You are a UNIL-CHUV scientist

and would like to create a start-up and

need a financial support to start

 

InnoPACTT image

Apply for a one-year InnoTREK grant to launch your UNIL-CHUV spin-off!

PACTT, Technology Transfer Office of UNIL-CHUV, is calling for start-up projects for the InnoTREK grant, part of InnoPACTT, a financial fund to accelerate innovation and UNIL-CHUV spin-off creation. With this InnoTREK support, PACTT wants to encourage researchers with innovative ideas to jump into the entrepreneurship adventure.

Deadline for application: April 18, 2016

Documents available on:

https://www.pactt.ch/innotrek/

For more information please contact us on:

innopactt.info@chuv.ch

Phones:         021.314.39.84/021.314.49.58/021 314.82.19

 

 

InnoSTEP: a proof of concept grant to bring your project to the next step

February 16, 2016

 

You are a UNIL-CHUV researcher

and you need to finance a proof-of-concept

or a prototype for your innovative project?

 

Stock_000065861769_web grand vert

Apply for an InnoSTEP grant!

PACTT, Technology Transfer Office of UNIL-CHUV, proposes InnoSTEP, a proof-of-concept grant of up to CHF 40’000 to accelerate innovation. With this support, PACTT wants to help the development of your innovative projects and its transfer to industrial partners.

Conditions of participation and forms:

For more information please contact us on: innopactt.info@chuv.ch

or by phones:         021.314.39.84/   021.314.49.58/   021 314.82.19

 

 

Prix Isabelle Musy pour les femmes entrepreneures en sciences et technologies

February 10, 2016

D’une valeur de CHF 50’000.-, il vise à encourager l’entrepreneuriat des femmes dans le domaine des sciences et des technologies.

Ce prix est ouvert aux femmes diplômées d’une haute école de Suisse Romande et du Tessin.

Attention, délai d’inscription jusqu’au 25 mars !

 

Pour plus d’informations sur les conditions et les délais : Site Vice Présidence innovation et valorisation EPFL

Business concept training

December 2, 2015

The direction of the University of Lausanne supports the development of entrepreneurship especially among its students and its researchers from all faculties. The university offers you the opportunity to take part in the next  Business Concept Training supported by the CTI (Commission for Technology and Innovation).

Are you inspired to create or join a start-up? Are you keen to acquire a first comprehensive skill set to make you operational and effective in a company? Are you looking for opportunities to go out of your daily work activity to link up with potential future co-founders / business partners?

Discover the fast track, hands on, Business Concept training, designed and taught by experts and experienced startup founders for ambitious researchers, students & faculty members from a University, a University of Applied Sciences or a research Institute.

In 10 evening sessions of individual coaching by entrepreneurs, you will learn how to think, act like an entrepreneur and transform an idea into business concept, to play multiple key roles in a startup. During an inter-regional team-building day at the beginning of the course, you will have the opportunity to meet other participants from different universities and domains. At the end of the semester, teams who submitted the best concepts are selected and rewarded with a prize enabling them to continue their development.

Apply before December 20, 2015 for the spring semester 2016 (Starting on February 23, 2016) and join our network of start-up founders! The admission is free but is subjected to a selection process. Your selection is confirmed in mid-January by email.

Good English knowledge will be necessary to follow the training.

Video

Informations/inscriptions

Lien direct pour l’inscription

Contact
Ramona Traber
business.concept@epfl-innovationpark.ch
Tel: +41 21 693 8336

Charity and academic collaboration aims to find drug treatment for lymphoma

September 29, 2015

London, UK, Lausanne, Switzerland, 24 September 2015, MRC Technology and the University of Lausanne are collaborating to find new drug treatments for diffuse large B cell lymphoma, the most common type of non-Hodgkin lymphoma.

MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1), an immunomodulatory enzyme, is required for the effective triggering of an immune response. However, dysregulation of MALT1 is also associated with some subsets of lymphoma, including diffuse large B cell lymphoma, suggesting that MALT1 could be a promising drug target for these types of cancer.

Professor Margot Thome-Miazza, Associate Professor, University of Lausanne said: “We have previously identified a novel way of regulating the catalytic activity of MALT1 via a protein modification called ubiquitination.  We are now working with MRC Technology to harness this regulatory mechanism and discover small molecule inhibitors that specifically interfere with the ubiquitin-linked form of MALT1.”

Justin Bryans, Director, Drug Discovery, MRC Technology said: “It is encouraging that we can build on the work of the University of Lausanne and bring new treatments to patients. These drugs could potentially also treat other types of lymphoma associated with MALT1 over-activity, for example MALT lymphoma and Mantle Cell lymphoma.”

Céline Lafourcade, Licensing manager at Powering Academia-industry Collaborations and Technology Transfer (PACTT) explained: “MRC Technology with its unique capabilities constitutes an ideal partner to further develop this innovative technology emanating from academic research.”

MALT1 inhibitors may also have wider therapeutic applications owing to MALT1’s role in immune regulation, and could potentially be used to limit overactive immune reactions in autoimmune diseases.

Contacts

At PACTT
Céline Lafourcade
Licensing manager
E: celine.lafourcade@chuv.ch
T: +41.21.314.49.58

At MRC Technology
Liezel Tipper
PR and Communications Manager
E: liezel.tipper@tech.mrc.ac.uk
T: +44 (0)20 7391 2772

About MRC Technology
MRC Technology is an independent life science medical research charity committed to drastically improving positive patient outcomes everywhere. As a champion for human health, MRC Technology partners with academic, biotechnology, pharmaceutical, and charity organisations to move promising medical research forward into viable and accessible patient treatments. Our people combine commercialisation and IP management skills with diagnostic and drug discovery expertise, specialising in small molecule and therapeutic antibodies. MRC Technology projects have led to the approved drugs Tysabri®, Actemra®, Entyvio® and Keytruda®, changing the lives of countless patients by harnessing the potential of science.

About the University of Lausanne
The University of Lausanne (UNIL) is composed of seven faculties, active in the field of Medicine, Life Sciences, Geosciences, Environment, Business, Humanities and Social Sciences. Approximately 14,000 students and 2,800 researchers, including 500 professors, study and work on its three campuses. The University of Lausanne comprises more than 180 teaching or research units that are working on projects of national and international significance. Interdisciplinarity (clinical science and fundamental sciences) within the Faculty of Biology and Medicine (FBM) is the key factor to open, fluid research, which has placed Lausanne University Hospital (CHUV) and the University of Lausanne at the forefront of life sciences.

About PACTT
Founded in February 2000, PACTT (Powering Academia-industry Collaborations and Technology Transfer) is the joint technology transfer office of the University of Lausanne (UNIL) and the University Hospital of Lausanne (CHUV). The primary mission is to transfer the researchers’ innovations to the economy for public benefit.

(source: MRCT)